Takeda new debts to EBITDA ratios targeted until 2023

Published by
Matej Mikulic,
Feb 12, 2019
This statistic depicts the targeted net debt to EBITDA ratio of Takeda Pharmaceutical after the Shire deal, until March 2023, by deleveraging case. The ratio of debts to EBITDA before the Shire deal in standalone deleveraging cases was 1.6.

Targeted net debt to EBITDA ratio of Takeda Pharmaceutical after Shire deal until 2023

Loading statistic...

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

January 2019

Region

Worldwide

Survey time period

as of January 2019

Supplementary notes

* Ratio for before Shire deal is as of March 2018.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Pharma and biotech M&A activity "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Pharma and biotech M&A activity

Industry overview

5

Number of deals

7

Value of deals

5

Mega-merger: BMS/Celgene

5

2021 outlook

4

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Pharmaceutical and biotech M&A activitiesGlobal pharmaceutical industryM&As worldwideM&As in EuropeM&As in the United States
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.